Regular use of aspirin and statins reduces the risk of cancer in individuals with systemic inflammatory diseases
Aspirin has shown potential for cancer prevention, but a recent large randomized controlled trial found no evidence for a reduction in cancer risk. Given the anti-inflammatory effects of aspirin, systemic inflammatory diseases (SIDs), such as osteoporosis, cardiovascular diseases, and metabolic diseases, could potentially modify the aspirin-cancer link. To investigate the impact of aspirin in people with SIDs, we conducted an observational study on a prospective cohort of 478,615 UK Biobank participants. Individuals with at least one of the 41 SIDs displayed a higher cancer risk than those without SIDs. Regular aspirin use showed protective effects exclusively in patients with SID, contrasting an elevated risk among their non-SID counterparts. Nonetheless, aspirin use demonstrated preventative potential only for 9 of 21 SID-associated cancer subtypes. Cholesterol emerged as another key mediator linking SIDs to cancer risk. Notably, regular statin use displayed protective properties in patients with SID but not in their non-SID counterparts. Concurrent use of aspirin and statins exhibited a stronger protective association in patients with SID, covering 14 common cancer subtypes. In summary, patients with SIDs may represent a population particularly responsive to regular aspirin and statin use. Promoting either combined or individual use of these medications within the context of SIDs could offer a promising chemoprevention strategy.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
---|---|
Enthalten in: |
Cancer research - (2024) vom: 27. März |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Lin, Jia-Run [VerfasserIn] |
---|
Links: |
---|
Themen: |
---|
Anmerkungen: |
Date Revised 27.03.2024 published: Print-Electronic Citation Status Publisher |
---|
doi: |
10.1158/0008-5472.CAN-23-2941 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM37025662X |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM37025662X | ||
003 | DE-627 | ||
005 | 20240328001337.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240328s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1158/0008-5472.CAN-23-2941 |2 doi | |
028 | 5 | 2 | |a pubmed24n1351.xml |
035 | |a (DE-627)NLM37025662X | ||
035 | |a (NLM)38536116 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Lin, Jia-Run |e verfasserin |4 aut | |
245 | 1 | 0 | |a Regular use of aspirin and statins reduces the risk of cancer in individuals with systemic inflammatory diseases |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Revised 27.03.2024 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status Publisher | ||
520 | |a Aspirin has shown potential for cancer prevention, but a recent large randomized controlled trial found no evidence for a reduction in cancer risk. Given the anti-inflammatory effects of aspirin, systemic inflammatory diseases (SIDs), such as osteoporosis, cardiovascular diseases, and metabolic diseases, could potentially modify the aspirin-cancer link. To investigate the impact of aspirin in people with SIDs, we conducted an observational study on a prospective cohort of 478,615 UK Biobank participants. Individuals with at least one of the 41 SIDs displayed a higher cancer risk than those without SIDs. Regular aspirin use showed protective effects exclusively in patients with SID, contrasting an elevated risk among their non-SID counterparts. Nonetheless, aspirin use demonstrated preventative potential only for 9 of 21 SID-associated cancer subtypes. Cholesterol emerged as another key mediator linking SIDs to cancer risk. Notably, regular statin use displayed protective properties in patients with SID but not in their non-SID counterparts. Concurrent use of aspirin and statins exhibited a stronger protective association in patients with SID, covering 14 common cancer subtypes. In summary, patients with SIDs may represent a population particularly responsive to regular aspirin and statin use. Promoting either combined or individual use of these medications within the context of SIDs could offer a promising chemoprevention strategy | ||
650 | 4 | |a Journal Article | |
700 | 1 | |a Han, Duan-Duan |e verfasserin |4 aut | |
700 | 1 | |a Wei, Wei |e verfasserin |4 aut | |
700 | 1 | |a Zeng, Qin |e verfasserin |4 aut | |
700 | 1 | |a Rong, Zi-Xuan |e verfasserin |4 aut | |
700 | 1 | |a Bai, Xue |e verfasserin |4 aut | |
700 | 1 | |a Zhang, Yan-Pei |e verfasserin |4 aut | |
700 | 1 | |a Wang, Jian |e verfasserin |4 aut | |
700 | 1 | |a Cai, Xiao-Ting |e verfasserin |4 aut | |
700 | 1 | |a Rao, Xu-Guang |e verfasserin |4 aut | |
700 | 1 | |a Ma, Si-Cong |e verfasserin |4 aut | |
700 | 1 | |a Dong, Zhong-Yi |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Cancer research |d 1945 |g (2024) vom: 27. März |w (DE-627)NLM000001740 |x 1538-7445 |7 nnns |
773 | 1 | 8 | |g year:2024 |g day:27 |g month:03 |
856 | 4 | 0 | |u http://dx.doi.org/10.1158/0008-5472.CAN-23-2941 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |j 2024 |b 27 |c 03 |